Class summary at a glance.

Every drug in the Peroxisome Proliferator Receptor alpha Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $176.1Mcombined across class
Total Rx claims: 9.0M2.9M unique beneficiaries
Generic mfrs (active): 45across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Fenofibrate

Brand: ANTARA · 3.1M Part D claims (CY24) · 982K beneficiaries · First FDA approval: 2005-05-13

26 generic mfrs 0 plans require PA

Low NADAC$0.079

→

Avg plan cost$0.561

Part D spend $89.1M 7× spread, current vs floor

Class share

51%

of class CY24 spend

View profile →

Pioglitazone

Brand: Actos · 4.9M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 1999-07-15

11 generic mfrs 3 plans require PA

Low NADAC$0.069

→

Avg plan cost$0.091

Part D spend $65.9M 1× spread, current vs floor

Class share

37%

of class CY24 spend

View profile →

Gemfibrozil

Brand: Lopid · 1.1M Part D claims (CY24) · 339K beneficiaries · First FDA approval: 1993-09-27

8 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.103

→

Avg plan cost$0.103

Part D spend $21.1M 1× spread, current vs floor

Class share

12%

of class CY24 spend

View profile →

Fenofibric Acid

— Part D claims (CY24) · First FDA approval: 2013-12-04

Brand-only (no generics) 0 plans require PA

Low NADAC$0.153

→

Avg plan cost$0.198

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.